Omeros (OMER) Q3 2026: Profit Beat Masks a Revenue Miss

As seen on the 24/7 Wall St. homepage on November 16, 2026.

OMER Omeros
Q3 2026
EPS
$0.06
est -$0.02 +400.0%
Revenue
$36M
est $37M -3.6%

Omeros turned a profit a quarter ahead of what analysts modeled, yet traders sold anyway after revenue came in missing the $37.3 million consensus. YARTEMLEA net product revenue still rose 26% sequentially, with Medicare NTAP payments live since October 1.

Continue ReadingShow less

Omeros posted non-GAAP earnings per share of $0.06 for the third quarter of 2026, beating expectations for a loss of $0.02. That is a meaningful inflection: analysts were still modeling a loss, and the company delivered a profit, extending a string of bottom-line beats that stretches back through most of 2026.

Revenue told a different story. Net product sales of $35.93 million came in short of the analyst target, and that gap was enough to send traders to the exits despite the earnings strength. All of that revenue came from YARTEMLEA, the company's TA-TMA therapy, whose net product sales climbed 26% sequentially from the prior quarter.

The GAAP result was sharply negative at a loss of $0.79 per share, but that number is almost entirely a bookkeeping event. A $62 million non-cash charge tied to mark-to-market adjustments on the derivative linked to the company's 2029 convertible notes drove the swing. Operating income and operating cash flow were both positive, reflecting the underlying commercial trajectory.

Sponsored

Two reimbursement catalysts give the Q4 and early 2027 outlook more texture than a typical quarterly setup. Medicare NTAP inpatient payments for YARTEMLEA went live on October 1, worth up to $287,079 per eligible case. Favorable Medicare outpatient reimbursement for 340B-acquired YARTEMLEA is set to begin January 1, 2027. CEO Gregory Demopulos said revenue growth has continued into the fourth quarter.

Beyond YARTEMLEA, Omeros remains eligible for up to $100 million in near-term milestones from Novo Nordisk tied to zaltenibart, a MASP-3 inhibitor. The company is also preparing clinical studies in hyperinflammatory ARDS and TA-TMA prevention, with initiation expected in late 2026 or early 2027, and a Phase 2 program for OMS1029 is being finalized.

Mentioned: OMER